We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Philip
Molyneaux
p.molyneaux@imperial.ac.uk
Dr
Philip
Molyneaux
p.molyneaux@imperial.ac.uk
Other respiratory diseases principally affecting the interstitium
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Pulmonary fibrosis or Interstitial Lung Disease (ILD) encompasses a wide spectrum of progressive and irreversible disorders destruction of the lung. Clinically this causes cough and progressive breathing difficulty, which in the majority of cases result in death. Currently, diagnosis is challenging, with a third of patients either falling outside of the current disease categories or are termed unclassifiable.
Recent studies have highlighted similarities in genetic predisposition across a range of ILDs. The pipeline from the genetic makeup of an individual to proteins that are constructed from these genes can be viewed as a disease ‘fingerprint’ and scientific discovery along this path can lead to new understanding of pathogenesis.
We hope to identify specific markers in the blood of patients with a range of ILDs that will sidestep conventional classifications, speeding up the diagnostic pathway and avoid some of the more invasive diagnostic tests currently being used in clinical practice. We hope to collect breath, blood, urine and stool samples, as well as surplus fluid samples from bronchoscopy (a test which will be performed in some patients as part of routine clinical practice). We aim to use the data to predict which patients have more aggressive disease and those that are likely to respond to treatment.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patients with co-morbid disease that in the opinion of the investigators gives them an expected life expectancy of less than one year will be excluded from the study. Patients who are participating in an interventional clinical trial will be excluded from enrolment in this study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by ACTION FOR PULMONARY FIBROSIS .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 47430
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
